1
|
Sánchez-Costa M, Urigoitia A, Comino N, Arnaiz B, Khatami N, Ruiz-Hernandez R, Diamanti E, Abarrategi A, López-Gallego F. In-Hydrogel Cell-Free Protein Expression System as Biocompatible and Implantable Biomaterial. ACS Appl Mater Interfaces 2024; 16:15993-16002. [PMID: 38509001 DOI: 10.1021/acsami.4c01388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
Biomaterials capable of delivering therapeutic proteins are relevant in biomedicine, yet their manufacturing relies on centralized manufacturing chains that pose challenges to their remote implementation at the point of care. This study explores the viability of confined cell-free protein synthesis within porous hydrogels as biomaterials that dynamically produce and deliver proteins to in vitro and in vivo biological microenvironments. These functional biomaterials have the potential to be assembled as implants at the point of care. To this aim, we first entrap cell-free extracts (CFEs) from Escherichia coli containing the transcription-translation machinery, together with plasmid DNA encoding the super folded green fluorescence protein (sGFP) as a model protein, into hydrogels using various preparation methods. Agarose hydrogels result in the most suitable biomaterials to confine the protein synthesis system, demonstrating efficient sGFP production and diffusion from the core to the surface of the hydrogel. Freeze-drying (FD) of agarose hydrogels still allows for the synthesis and diffusion of sGFP, yielding a more attractive biomaterial for its reconstitution and implementation at the point of care. FD-agarose hydrogels are biocompatible in vitro, allowing for the colonization of cell microenvironments along with cell proliferation. Implantation assays of this biomaterial in a preclinical mouse model proved the feasibility of this protein synthesis approach in an in vivo context and indicated that the physical properties of the biomaterials influence their immune responses. This work introduces a promising avenue for biomaterial fabrication, enabling the in vivo synthesis and targeted delivery of proteins and opening new paths for advanced protein therapeutic approaches based on biocompatible biomaterials.
Collapse
Affiliation(s)
| | - Ane Urigoitia
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
| | - Natalia Comino
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
| | - Blanca Arnaiz
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
| | - Neda Khatami
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
- Polymat, University of Basque Country UPV/EHU, Donostia/San Sebastián 20018, Gipuzkoa, Spain
| | | | - Eleftheria Diamanti
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
| | - Ander Abarrategi
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
- IKERBASQUE, Basque Foundation for Science, 48013Bilbao, Spain
| | - Fernando López-Gallego
- CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009Donostia, Spain
- IKERBASQUE, Basque Foundation for Science, 48013Bilbao, Spain
| |
Collapse
|
2
|
Khatami N, Guerrero P, Martín P, Quintela E, Ramos V, Saa L, Cortajarena AL, de la Caba K, Camarero-Espinosa S, Abarrategi A. Valorization of biological waste from insect-based food industry: Assessment of chitin and chitosan potential. Carbohydr Polym 2024; 324:121529. [PMID: 37985106 DOI: 10.1016/j.carbpol.2023.121529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 09/21/2023] [Accepted: 10/23/2023] [Indexed: 11/22/2023]
Abstract
Edible mealworms can be farmed to produce high-quality nutrients and proteins, useful as ingredients in human and animal foods. During this process biological waste is produced. This work explores the usage of the biological waste as source to produce chitin and chitosan with different potential applications. Different waste fractions were processed, and the feasibility of chitin isolation was assessed. Chitosan was derived, and films were fabricated and tested for intended uses. Data indicate that biopolymers with different properties can be obtained from multiple biological waste fractions. All samples show antibacterial activity, while chitosan films derived from molt show interesting properties for packaging purposes. Films also trigger the expression of anti-inflammatory phenotype markers in macrophage cells, which may be useful for tissue engineering implantation purposes. Altogether, biological waste from insect farming can be used to extract chitin and chitosan with different properties, and therefore, suitable for different applications.
Collapse
Affiliation(s)
- Neda Khatami
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; POLYMAT, University of Basque Country UPV/EHU, Donostia/San Sebastián 20018, Gipuzkoa, Spain
| | - Pedro Guerrero
- BIOMAT Research Group, University of the Basque Country (UPV/EHU), Escuela de Ingeniería de Gipuzkoa, Plaza de Europa 1, 20018 Donostia-San Sebastián, Spain; BCMaterials, Basque Center for Materials, Applications and Nanostructures, UPV/EHU Science Park, 48940 Leioa, Spain
| | - Pablo Martín
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain
| | | | - Viviana Ramos
- Noricum SL, Avda. Fuente Nueva 14, nave 3, 28703 San Sebastián de los Reyes, Madrid, Spain
| | - Laura Saa
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain
| | - Aitziber L Cortajarena
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
| | - Koro de la Caba
- BIOMAT Research Group, University of the Basque Country (UPV/EHU), Escuela de Ingeniería de Gipuzkoa, Plaza de Europa 1, 20018 Donostia-San Sebastián, Spain; BCMaterials, Basque Center for Materials, Applications and Nanostructures, UPV/EHU Science Park, 48940 Leioa, Spain
| | - Sandra Camarero-Espinosa
- POLYMAT, University of Basque Country UPV/EHU, Donostia/San Sebastián 20018, Gipuzkoa, Spain; IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
| | - Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain.
| |
Collapse
|
3
|
Ramos-Díez S, Larrañaga-Jaurrieta G, Iturriaga L, Abarrategi A, Camarero-Espinosa S. Low molecular weight poly((D,L)-lactide- co-caprolactone) liquid inks for diluent-free DLP printing of cell culture platforms. Biomater Sci 2023. [PMID: 37435668 DOI: 10.1039/d3bm00581j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/13/2023]
Abstract
Digital light processing (DLP) printing offers the possibility of fabricating complex objects in a fast and reproducible manner. A main requirement for DLP printing is the use of inks with low viscosities that can flow under the printing platform in a short period of time. Its exploitation in tissue engineering applications has been centered on the use of hydrogel forming materials diluted in aqueous solutions or the use of polyesters in combination with diluents and heating platforms that aid in the reduction of their viscosity. The use of diluents, however, modifies the mechanical properties and reduces the shape fidelity of the printed objects and, the use of heating platforms results in vats with heterogeneous temperatures and ink viscosities. Here, we report on the synthesis of a library of methacrylated low molecular weight (<3000 g mol-1) homopolymers ((P(D,L)LA and PCL) and copolymers (P((D,L)LA-co-CL)) of 2- and 3-arms based on (D,L)-lactide and ε-caprolactone. The resulting inks possessed low viscosity that made them printable in the absence of diluents and heating elements. DLP printing of cubical and cylindrical patterns resulted in objects with a higher shape fidelity than their counterparts fabricated using diluents and with printed features on the order of 300 μm. The printed materials were biocompatible and supported the growth of human mesenchymal stem cells (hMSCs). Moreover, the variations in the composition resulted in polymers that enabled the attachment of hMSCs to different extents, leading to the formation of well-adhered cell monolayers or loosely adhered cell aggregates.
Collapse
Affiliation(s)
- Sandra Ramos-Díez
- BioSmarTE Lab, POLYMAT, University of Basque Country UPV / EHU, Donostia / San Sebastián 20018, Gipuzkoa, Spain.
| | - Garazi Larrañaga-Jaurrieta
- BioSmarTE Lab, POLYMAT, University of Basque Country UPV / EHU, Donostia / San Sebastián 20018, Gipuzkoa, Spain.
- Regenerative Medicine Lab, CICbiomaGUNE, Donostia / San Sebastián 20014, Gipuzkoa, Spain
| | - Leire Iturriaga
- BioSmarTE Lab, POLYMAT, University of Basque Country UPV / EHU, Donostia / San Sebastián 20018, Gipuzkoa, Spain.
| | - Ander Abarrategi
- Regenerative Medicine Lab, CICbiomaGUNE, Donostia / San Sebastián 20014, Gipuzkoa, Spain
- Ikerbasque, Basque Foundation for Science, Euskadi Pl., 5, 48009, Bilbao, Spain
| | - Sandra Camarero-Espinosa
- BioSmarTE Lab, POLYMAT, University of Basque Country UPV / EHU, Donostia / San Sebastián 20018, Gipuzkoa, Spain.
- Ikerbasque, Basque Foundation for Science, Euskadi Pl., 5, 48009, Bilbao, Spain
| |
Collapse
|
4
|
Sanz-Horta R, Retegi-Carrion S, Ruiz-Hernandez R, Khatami N, Elvira C, Martinez-Campos E, Rodríguez-Hernández J, Abarrategi A. Polycaprolactone with multiscale porosity and patterned surface topography prepared using sacrificial 3D printed moulds: Towards tailor-made scaffolds. Biomater Adv 2023; 151:213465. [PMID: 37236118 DOI: 10.1016/j.bioadv.2023.213465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 04/24/2023] [Accepted: 05/05/2023] [Indexed: 05/28/2023]
Abstract
Biocompatible three-dimensional porous scaffolds are widely used in multiple biomedical applications. However, the fabrication of tailor-made 3D structures with controlled and combined multiscale macroscopic-microscopic, surface and inner porosities in a straightforward manner is still a current challenge. Herein, we use multimaterial fused deposition modeling (FDM) to generate poly (vinyl alcohol) (PVA) sacrificial moulds filled with poly (Ɛ-caprolactone) (PCL) to generate well defined PCL 3D objects. Further on, the supercritical CO2 (SCCO2) technique, as well as the breath figures mechanism (BFs), were additionally employed to fabricate specific porous structures at the core and surfaces of the 3D PCL object, respectively. The biocompatibility of the resulting multiporous 3D structures was tested in vitro and in vivo, and the versatility of the approach was assessed by generating a vertebra model fully tunable at multiple pore size levels. In sum, the combinatorial strategy to generate porous scaffolds offers unique possibilities to fabricate intricate structures by combining the advantages of additive manufacturing (AM), which provides flexibility and versatility to generate large sized 3D structures, with advantages of the SCCO2 and BFs techniques, which allow to finely tune the macro and micro porosity at material surface and material core levels.
Collapse
Affiliation(s)
- Raúl Sanz-Horta
- Institute of Polymer Science and Technology, ICTP-CSIC, Department of Applied Macromolecular Chemistry, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Sugoi Retegi-Carrion
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain
| | - Raquel Ruiz-Hernandez
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain
| | - Neda Khatami
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain
| | - Carlos Elvira
- Institute of Polymer Science and Technology, ICTP-CSIC, Department of Applied Macromolecular Chemistry, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Enrique Martinez-Campos
- Institute of Polymer Science and Technology, ICTP-CSIC, Department of Applied Macromolecular Chemistry, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Juan Rodríguez-Hernández
- Institute of Polymer Science and Technology, ICTP-CSIC, Department of Applied Macromolecular Chemistry, Juan de la Cierva 3, 28006 Madrid, Spain.
| | - Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.
| |
Collapse
|
5
|
Berastegui N, Ainciburu M, Romero JP, Garcia-Olloqui P, Alfonso-Pierola A, Philippe C, Vilas-Zornoza A, San Martin-Uriz P, Ruiz-Hernández R, Abarrategi A, Ordoñez R, Alignani D, Sarvide S, Castro-Labrador L, Lamo-Espinosa JM, San-Julian M, Jimenez T, López-Cadenas F, Muntion S, Sanchez-Guijo F, Molero A, Montoro MJ, Tazón B, Serrano G, Diaz-Mazkiaran A, Hernaez M, Huerga S, Bewicke-Copley F, Rio-Machin A, Maurano MT, Díez-Campelo M, Valcarcel D, Rouault-Pierre K, Lara-Astiaso D, Ezponda T, Prosper F. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes. Nat Commun 2022; 13:7619. [PMID: 36494342 PMCID: PMC9734135 DOI: 10.1038/s41467-022-35192-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 11/21/2022] [Indexed: 12/13/2022] Open
Abstract
Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis, with increased incidence in older individuals. Here we analyze the transcriptome of human HSCs purified from young and older healthy adults, as well as MDS patients, identifying transcriptional alterations following different patterns of expression. While aging-associated lesions seem to predispose HSCs to myeloid transformation, disease-specific alterations may trigger MDS development. Among MDS-specific lesions, we detect the upregulation of the transcription factor DNA Damage Inducible Transcript 3 (DDIT3). Overexpression of DDIT3 in human healthy HSCs induces an MDS-like transcriptional state, and dyserythropoiesis, an effect associated with a failure in the activation of transcriptional programs required for normal erythroid differentiation. Moreover, DDIT3 knockdown in CD34+ cells from MDS patients with anemia is able to restore erythropoiesis. These results identify DDIT3 as a driver of dyserythropoiesis, and a potential therapeutic target to restore the inefficient erythroid differentiation characterizing MDS patients.
Collapse
Affiliation(s)
- Nerea Berastegui
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Marina Ainciburu
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Juan P. Romero
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Paula Garcia-Olloqui
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Ana Alfonso-Pierola
- grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ,grid.411730.00000 0001 2191 685XDepartment of Hematology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN, 31008 Pamplona, Spain
| | - Céline Philippe
- grid.4868.20000 0001 2171 1133Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, England UK
| | - Amaia Vilas-Zornoza
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Patxi San Martin-Uriz
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| | - Raquel Ruiz-Hernández
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain
| | - Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain ,grid.424810.b0000 0004 0467 2314Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - Raquel Ordoñez
- grid.137628.90000 0004 1936 8753Institute for Systems Genetics, NYU School of Medicine, New York, NY USA
| | - Diego Alignani
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Sarai Sarvide
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Laura Castro-Labrador
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - José M. Lamo-Espinosa
- grid.411730.00000 0001 2191 685XDepartment of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN, 31008 Pamplona, Spain
| | - Mikel San-Julian
- grid.411730.00000 0001 2191 685XDepartment of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN, 31008 Pamplona, Spain
| | - Tamara Jimenez
- grid.11762.330000 0001 2180 1817Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain
| | - Félix López-Cadenas
- grid.11762.330000 0001 2180 1817Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain
| | - Sandra Muntion
- grid.11762.330000 0001 2180 1817Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain
| | - Fermin Sanchez-Guijo
- grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ,grid.11762.330000 0001 2180 1817Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain
| | - Antonieta Molero
- grid.411083.f0000 0001 0675 8654Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - Maria Julia Montoro
- grid.411083.f0000 0001 0675 8654Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - Bárbara Tazón
- grid.411083.f0000 0001 0675 8654Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - Guillermo Serrano
- grid.508840.10000 0004 7662 6114Computational Biology Program, Institute for data science and artificial intelligence (datai), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Navarra, Spain
| | - Aintzane Diaz-Mazkiaran
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.508840.10000 0004 7662 6114Computational Biology Program, Institute for data science and artificial intelligence (datai), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Navarra, Spain
| | - Mikel Hernaez
- grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ,grid.508840.10000 0004 7662 6114Computational Biology Program, Institute for data science and artificial intelligence (datai), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Navarra, Spain
| | - Sofía Huerga
- grid.411730.00000 0001 2191 685XDepartment of Hematology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN, 31008 Pamplona, Spain
| | - Findlay Bewicke-Copley
- grid.4868.20000 0001 2171 1133Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Ana Rio-Machin
- grid.4868.20000 0001 2171 1133Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Matthew T. Maurano
- grid.137628.90000 0004 1936 8753Institute for Systems Genetics, NYU School of Medicine, New York, NY USA ,grid.137628.90000 0004 1936 8753Department of Pathology, NYU School of Medicine, New York, NY USA
| | - María Díez-Campelo
- grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ,grid.11762.330000 0001 2180 1817Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain
| | - David Valcarcel
- grid.411083.f0000 0001 0675 8654Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - Kevin Rouault-Pierre
- grid.4868.20000 0001 2171 1133Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, England UK
| | - David Lara-Astiaso
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| | - Teresa Ezponda
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
| | - Felipe Prosper
- grid.508840.10000 0004 7662 6114Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ,grid.411730.00000 0001 2191 685XDepartment of Hematology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN, 31008 Pamplona, Spain
| |
Collapse
|
6
|
Iazzolino G, Mendibil U, Arnaiz B, Ruiz-de-Angulo A, Azkargorta M, Uribe KB, Khatami N, Elortza F, Olalde B, Gomez-Vallejo V, Llop J, Abarrategi A. Decellularization of xenografted tumors provides cell-specific in vitro 3D environment. Front Oncol 2022; 12:956940. [PMID: 36059712 PMCID: PMC9434107 DOI: 10.3389/fonc.2022.956940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 07/25/2022] [Indexed: 11/13/2022] Open
Abstract
In vitro cell culture studies are common in the cancer research field, and reliable biomimetic 3D models are needed to ensure physiological relevance. In this manuscript, we hypothesized that decellularized xenograft tumors can serve as an optimal 3D substrate to generate a top-down approach for in vitro tumor modeling. Multiple tumor cell lines were xenografted and the formed solid tumors were recovered for their decellularization by several techniques and further characterization by histology and proteomics techniques. Selected decellularized tumor xenograft samples were seeded with the HCC1806 human triple-negative breast cancer (TNBC) basal-like subtype cell line, and cell behavior was compared among them and with other control 2D and 3D cell culture methods. A soft treatment using Freeze-EDTA-DNAse allows proper decellularization of xenografted tumor samples. Interestingly, proteomic data show that samples decellularized from TNBC basal-like subtype xenograft models had different extracellular matrix (ECM) compositions compared to the rest of the xenograft tumors tested. The in vitro recellularization of decellularized ECM (dECM) yields tumor-type–specific cell behavior in the TNBC context. Data show that dECM derived from xenograft tumors is a feasible substrate for reseeding purposes, thereby promoting tumor-type–specific cell behavior. These data serve as a proof-of-concept for further potential generation of patient-specific in vitro research models.
Collapse
Affiliation(s)
- Gaia Iazzolino
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Unai Mendibil
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
- TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Blanca Arnaiz
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Ane Ruiz-de-Angulo
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Mikel Azkargorta
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain
| | - Kepa B. Uribe
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Neda Khatami
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Felix Elortza
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain
| | - Beatriz Olalde
- TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Vanessa Gomez-Vallejo
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Jordi Llop
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
- Ikerbasque, Basque Foundation for Science, Bilbao, Spain
- *Correspondence: Ander Abarrategi,
| |
Collapse
|
7
|
Passaro D, Garcia-Albornoz M, Diana G, Chakravarty P, Ariza-McNaughton L, Batsivari A, Borràs-Eroles C, Abarrategi A, Waclawiczek A, Ombrato L, Malanchi I, Gribben J, Bonnet D. Integrated OMICs unveil the bone-marrow microenvironment in human leukemia. Cell Rep 2021; 35:109119. [PMID: 33979628 PMCID: PMC8131581 DOI: 10.1016/j.celrep.2021.109119] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 01/20/2021] [Accepted: 04/21/2021] [Indexed: 12/21/2022] Open
Abstract
The bone-marrow (BM) niche is the spatial environment composed by a network of multiple stromal components regulating adult hematopoiesis. We use multi-omics and computational tools to analyze multiple BM environmental compartments and decipher their mutual interactions in the context of acute myeloid leukemia (AML) xenografts. Under homeostatic conditions, we find a considerable overlap between niche populations identified using current markers. Our analysis defines eight functional clusters of genes informing on the cellular identity and function of the different subpopulations and pointing at specific stromal interrelationships. We describe how these transcriptomic profiles change during human AML development and, by using a proximity-based molecular approach, we identify early disease onset deregulated genes in the mesenchymal compartment. Finally, we analyze the BM proteomic secretome in the presence of AML and integrate it with the transcriptome to predict signaling nodes involved in niche alteration in AML.
Collapse
Affiliation(s)
- Diana Passaro
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
| | - Manuel Garcia-Albornoz
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Giovanni Diana
- Dynamic Neuronal Imaging Unit, Pasteur Institute, CNRS UMR, 3571 Paris, France
| | - Probir Chakravarty
- Bioinformatic Core Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Linda Ariza-McNaughton
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Antoniana Batsivari
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Clara Borràs-Eroles
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Alexander Waclawiczek
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Luigi Ombrato
- Tumour-Host Interaction Laboratory, The Francis Crick Institute, London NW1 1AT, UK
| | - Ilaria Malanchi
- Tumour-Host Interaction Laboratory, The Francis Crick Institute, London NW1 1AT, UK
| | - John Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
| |
Collapse
|
8
|
Mian SA, Abarrategi A, Kong KL, Rouault-Pierre K, Wood H, Oedekoven CA, Smith AE, Batsivari A, Ariza-McNaughton L, Johnson P, Snoeks T, Mufti GJ, Bonnet D. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov 2021; 2:135-145. [PMID: 33778768 PMCID: PMC7610449 DOI: 10.1158/2643-3230.bcd-20-0161] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 11/12/2020] [Accepted: 12/18/2020] [Indexed: 12/13/2022] Open
Abstract
Myelodysplastic syndrome (MDS) are clonal stem cell diseases characterized mainly by ineffective hematopoiesis. Here, we present an approach that enables robust long-term engraftment of primary MDS stem cells (MDS-SCs) in mice by implantation of human mesenchymal cell-seeded scaffolds. Critically for modelling MDS, where patient sample material is limiting, mononuclear bone marrow cells containing as few as 104 CD34+ cells can be engrafted and expanded by this approach with the maintenance of the genetic make-up seen in the patients. Non-invasive high-resolution ultrasound imaging shows that these scaffolds are fully perfused. Our data shows that human microenvironment but not mouse is essential to MDS-SCs homing and engraftment. Notably, the alternative niche provided by healthy donor MSCs enhanced engraftment of MDS-SCs. This study characterizes a new tool to model MDS human disease with the level of engraftment previously unattainable in mice, and offers insights into human-specific determinants of MDS-SC microenvironment.
Collapse
Affiliation(s)
- Syed A Mian
- Department of Haematology, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom
| | - Ander Abarrategi
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom
| | - Kar Lok Kong
- Department of Haematology, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
| | - Kevin Rouault-Pierre
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom
| | - Henry Wood
- Department of Haematology, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
- King's College Hospital London, London, United Kingdom
| | - Caroline A Oedekoven
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom
| | - Alexander E Smith
- Department of Haematology, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
- King's College Hospital London, London, United Kingdom
| | - Antoniana Batsivari
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom
| | | | - Peter Johnson
- Imaging Research Facility, The Francis Crick Institute, London, United Kingdom
| | - Thomas Snoeks
- Imaging Research Facility, The Francis Crick Institute, London, United Kingdom
| | - Ghulam J Mufti
- Department of Haematology, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
- King's College Hospital London, London, United Kingdom
| | - Dominique Bonnet
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, United Kingdom.
| |
Collapse
|
9
|
Mendibil U, Ruiz-Hernandez R, Retegi-Carrion S, Garcia-Urquia N, Olalde-Graells B, Abarrategi A. Tissue-Specific Decellularization Methods: Rationale and Strategies to Achieve Regenerative Compounds. Int J Mol Sci 2020; 21:E5447. [PMID: 32751654 PMCID: PMC7432490 DOI: 10.3390/ijms21155447] [Citation(s) in RCA: 124] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 07/25/2020] [Accepted: 07/28/2020] [Indexed: 02/07/2023] Open
Abstract
The extracellular matrix (ECM) is a complex network with multiple functions, including specific functions during tissue regeneration. Precisely, the properties of the ECM have been thoroughly used in tissue engineering and regenerative medicine research, aiming to restore the function of damaged or dysfunctional tissues. Tissue decellularization is gaining momentum as a technique to obtain potentially implantable decellularized extracellular matrix (dECM) with well-preserved key components. Interestingly, the tissue-specific dECM is becoming a feasible option to carry out regenerative medicine research, with multiple advantages compared to other approaches. This review provides an overview of the most common methods used to obtain the dECM and summarizes the strategies adopted to decellularize specific tissues, aiming to provide a helpful guide for future research development.
Collapse
Affiliation(s)
- Unai Mendibil
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; (U.M.); (R.R.-H.); (S.R.-C.)
- TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain; (N.G.-U.); (B.O.-G.)
| | - Raquel Ruiz-Hernandez
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; (U.M.); (R.R.-H.); (S.R.-C.)
| | - Sugoi Retegi-Carrion
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; (U.M.); (R.R.-H.); (S.R.-C.)
| | - Nerea Garcia-Urquia
- TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain; (N.G.-U.); (B.O.-G.)
| | - Beatriz Olalde-Graells
- TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain; (N.G.-U.); (B.O.-G.)
| | - Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San Sebastian, Spain; (U.M.); (R.R.-H.); (S.R.-C.)
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| |
Collapse
|
10
|
Waclawiczek A, Hamilton A, Rouault-Pierre K, Abarrategi A, Albornoz MG, Miraki-Moud F, Bah N, Gribben J, Fitzgibbon J, Taussig D, Bonnet D. Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. J Clin Invest 2020; 130:3038-3050. [PMID: 32364536 PMCID: PMC7260026 DOI: 10.1172/jci133187] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Accepted: 02/26/2020] [Indexed: 12/12/2022] Open
Abstract
Acute myeloid leukemia (AML) disrupts the generation of normal blood cells, predisposing patients to hemorrhage, anemia, and infections. Differentiation and proliferation of residual normal hematopoietic stem and progenitor cells (HSPCs) are impeded in AML-infiltrated bone marrow (BM). The underlying mechanisms and interactions of residual hematopoietic stem cells (HSCs) within the leukemic niche are poorly understood, especially in the human context. To mimic AML infiltration and dissect the cellular crosstalk in human BM, we established humanized ex vivo and in vivo niche models comprising AML cells, normal HSPCs, and mesenchymal stromal cells (MSCs). Both models replicated the suppression of phenotypically defined HSPC differentiation without affecting their viability. As occurs in AML patients, the majority of HSPCs were quiescent and showed enrichment of functional HSCs. HSPC suppression was largely dependent on secreted factors produced by transcriptionally remodeled MSCs. Secretome analysis and functional validation revealed MSC-derived stanniocalcin 1 (STC1) and its transcriptional regulator HIF-1α as limiting factors for HSPC proliferation. Abrogation of either STC1 or HIF-1α alleviated HSPC suppression by AML. This study provides a humanized model to study the crosstalk among HSPCs, leukemia, and their MSC niche, and a molecular mechanism whereby AML impairs normal hematopoiesis by remodeling the mesenchymal niche.
Collapse
MESH Headings
- Animals
- Female
- Glycoproteins/genetics
- Glycoproteins/metabolism
- HL-60 Cells
- Hematopoiesis
- Hematopoietic Stem Cells/metabolism
- Hematopoietic Stem Cells/pathology
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit/genetics
- Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/metabolism
- Leukemia, Myeloid, Acute/pathology
- Male
- Mesenchymal Stem Cells/metabolism
- Mesenchymal Stem Cells/pathology
- Mice
- Mice, Inbred NOD
- Mice, Knockout
- Mice, SCID
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- U937 Cells
Collapse
Affiliation(s)
- Alexander Waclawiczek
- Haematopoietic Stem Cell Laboratory, Francis Crick Institute, London, United Kingdom
| | - Ashley Hamilton
- Haematopoietic Stem Cell Laboratory, Francis Crick Institute, London, United Kingdom
| | - Kevin Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, Francis Crick Institute, London, United Kingdom
| | - Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, Francis Crick Institute, London, United Kingdom
| | | | - Farideh Miraki-Moud
- Haemato-Oncology Unit, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
| | - Nourdine Bah
- Bioinformatic Core Facility, Francis Crick Institute, London, United Kingdom
| | - John Gribben
- Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Jude Fitzgibbon
- Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - David Taussig
- Haemato-Oncology Unit, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, Francis Crick Institute, London, United Kingdom
| |
Collapse
|
11
|
Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia 2020; 34:1658-1668. [PMID: 31776464 PMCID: PMC7266742 DOI: 10.1038/s41375-019-0662-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 10/28/2019] [Accepted: 11/17/2019] [Indexed: 11/25/2022]
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the nature of JMML-propagating cells (JMML-PCs) and the clonal architecture of the disease remained until now elusive. Combining genomic (exome, RNA-seq), Colony forming assay and xenograft studies, we detect the presence of JMML-PCs that faithfully reproduce JMML features including the complex/nonlinear organization of dominant/minor clones, both at diagnosis and relapse. Further integrated analysis also reveals that although the mutations are acquired in hematopoietic stem cells, JMML-PCs are not always restricted to this compartment, highlighting the heterogeneity of the disease during the initiation steps. We show that the hematopoietic stem/progenitor cell phenotype is globally maintained in JMML despite overexpression of CD90/THY-1 in a subset of patients. This study shed new lights into the ontogeny of JMML, and the identity of JMML-PCs, and provides robust models to monitor the disease and test novel therapeutic approaches.
Collapse
Affiliation(s)
- Aurélie Caye
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Kevin Rouault-Pierre
- Francis Crick Institute, London, UK
- Barts Cancer Institute, Centre for Haemato-Oncology, Queen Mary University of London, London, UK
| | - Marion Strullu
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Elodie Lainey
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Service d'Hématologie Biologique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | | | - Odile Fenneteau
- Service d'Hématologie Biologique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Chloé Arfeuille
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Jennifer Osman
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Bruno Cassinat
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Service de Biologie Cellulaire, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Sabrina Pereira
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | | | | | | | - Vincent Barlogis
- Service d'Hématologie Pédiatrique, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille (AP-HM), Marseille, France
| | - Jean-Hugues Dalle
- Service d'Hématologie pédiatrique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - André Baruchel
- Service d'Hématologie pédiatrique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Christine Chomienne
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
- Service de Biologie Cellulaire, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Hélène Cavé
- INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
| | | |
Collapse
|
12
|
Kurelac I, Abarrategi A, Ragazzi M, Iommarini L, Ganesh NU, Snoeks T, Bonnet D, Porcelli AM, Malanchi I, Gasparre G. A Humanized Bone Niche Model Reveals Bone Tissue Preservation Upon Targeting Mitochondrial Complex I in Pseudo-Orthotopic Osteosarcoma. J Clin Med 2019; 8:E2184. [PMID: 31835761 PMCID: PMC6947153 DOI: 10.3390/jcm8122184] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2019] [Revised: 12/07/2019] [Accepted: 12/09/2019] [Indexed: 12/23/2022] Open
Abstract
A cogent issue in cancer research is how to account for the effects of tumor microenvironment (TME) on the response to therapy, warranting the need to adopt adequate in vitro and in vivo models. This is particularly relevant in the development of strategies targeting cancer metabolism, as they will inevitably have systemic effects. For example, inhibition of mitochondrial complex I (CI), despite showing promising results as an anticancer approach, triggers TME-mediated survival mechanisms in subcutaneous osteosarcoma xenografts, a response that may vary according to whether the tumors are induced via subcutaneous injection or by intrabone orthotopic transplantation. Thus, with the aim to characterize the TME of CI-deficient tumors in a model that more faithfully represents osteosarcoma development, we set up a humanized bone niche ectopic graft. A prominent involvement of TME was revealed in CI-deficient tumors, characterized by the abundance of cancer associated fibroblasts, tumor associated macrophages and preservation of osteocytes and osteoblasts in the mineralized bone matrix. The pseudo-orthotopic approach allowed investigation of osteosarcoma progression in a bone-like microenvironment setting, without being invasive as the intrabone cell transplantation. Additionally, establishing osteosarcomas in a humanized bone niche model identified a peculiar association between targeting CI and bone tissue preservation.
Collapse
Affiliation(s)
- Ivana Kurelac
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy; (N.U.G.); (G.G.)
- Tumor-Host Interaction Lab, The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK;
| | - Ander Abarrategi
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK (D.B.)
- Regenerative Medicine Lab, CICbiomaGUNE, Paseo Miramón 182, 20014 Donostia, Spain
- Ikerbasque, Basque Foundation of Science, Maria Diaz de Haro 3, 48013 Bilbao, Spain
| | - Moira Ragazzi
- Anatomia Patologica, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy;
| | - Luisa Iommarini
- Dipartimento di Farmacia e Biotecnologie, Università di Bologna, Via Selmi 3, 40126 Bologna, Italy; (L.I.); (A.M.P.)
| | - Nikkitha Umesh Ganesh
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy; (N.U.G.); (G.G.)
| | - Thomas Snoeks
- In Vivo Imaging Operations, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK;
| | - Dominique Bonnet
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK (D.B.)
| | - Anna Maria Porcelli
- Dipartimento di Farmacia e Biotecnologie, Università di Bologna, Via Selmi 3, 40126 Bologna, Italy; (L.I.); (A.M.P.)
- Centro Interdipartimentale di Ricerca Industriale Scienze della Vita e Tecnologie per la Salute, Università di Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano dell’Emilia, Italy
| | - Ilaria Malanchi
- Tumor-Host Interaction Lab, The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK;
| | - Giuseppe Gasparre
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy; (N.U.G.); (G.G.)
- Centro di Ricerca Biomedica Applicata (CRBA), Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy
| |
Collapse
|
13
|
Abarrategi A, Gambera S, Alfranca A, Rodriguez-Milla MA, Perez-Tavarez R, Rouault-Pierre K, Waclawiczek A, Chakravarty P, Mulero F, Trigueros C, Navarro S, Bonnet D, García-Castro J. c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells. Sci Rep 2018; 8:15615. [PMID: 30353072 PMCID: PMC6199246 DOI: 10.1038/s41598-018-33689-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 10/03/2018] [Indexed: 12/15/2022] Open
Abstract
Mesenchymal progenitor cells (MPCs) have been hypothesized as cells of origin for sarcomas, and c-Fos transcription factor has been showed to act as an oncogene in bone tumors. In this study, we show c-Fos is present in most sarcomas with chondral phenotype, while multiple other genes are related to c-Fos expression pattern. To further define the role of c-Fos in sarcomagenesis, we expressed it in primary human MPCs (hMPCs), immortalized hMPCs and transformed murine MPCs (mMPCs). In immortalized hMPCs, c-Fos expression generated morphological changes, reduced mobility capacity and impaired adipogenic- and osteogenic-differentiation potentials. Remarkably, immortalized hMPCs or mMPCs expressing c-Fos generated tumors harboring a chondrogenic phenotype and morphology. Thus, here we show that c-Fos protein has a key role in sarcomas and that c-Fos expression in immortalized MPCs yields cell transformation and chondrogenic tumor formation.
Collapse
Affiliation(s)
- Ander Abarrategi
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, E-28021, Spain
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, WC2A 3LY, UK
| | - Stefano Gambera
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, E-28021, Spain
| | - Arantzazu Alfranca
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, E-28021, Spain
| | | | | | - Kevin Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, WC2A 3LY, UK
| | - Alexander Waclawiczek
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, WC2A 3LY, UK
| | - Probir Chakravarty
- Bioinformatics Core, The Francis Crick Institute, London, United Kingdom
| | - Francisca Mulero
- Molecular Image Core Unit, Spanish National Cancer Research Centre, Madrid, E-28029, Spain
| | - César Trigueros
- Mesenchymal and Hematopoietic Stem Cell Laboratory, Fundación Inbiomed, San Sebastian, E-20009, Spain
| | - Samuel Navarro
- Pathology Department, University of Valencia, Valencia, E-46010, Spain
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, WC2A 3LY, UK
| | - Javier García-Castro
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, E-28021, Spain.
| |
Collapse
|
14
|
Gambera S, Abarrategi A, González-Camacho F, Morales-Molina Á, Roma J, Alfranca A, García-Castro J. Clonal dynamics in osteosarcoma defined by RGB marking. Nat Commun 2018; 9:3994. [PMID: 30266933 PMCID: PMC6162235 DOI: 10.1038/s41467-018-06401-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Accepted: 09/03/2018] [Indexed: 02/06/2023] Open
Abstract
Osteosarcoma is a type of bone tumour characterized by considerable levels of phenotypic heterogeneity, aneuploidy, and a high mutational rate. The life expectancy of osteosarcoma patients has not changed during the last three decades and thus much remains to be learned about the disease biology. Here, we employ a RGB-based single-cell tracking system to study the clonal dynamics occurring in a de novo-induced murine osteosarcoma model. We show that osteosarcoma cells present initial polyclonal dynamics, followed by clonal dominance associated with adaptation to the microenvironment. Interestingly, the dominant clones are composed of subclones with a similar tumour generation potential when they are re-implanted in mice. Moreover, individual spontaneous metastases are clonal or oligoclonal, but they have a different cellular origin than the dominant clones present in primary tumours. In summary, we present evidence that osteosarcomagenesis can follow a neutral evolution model, in which different cancer clones coexist and propagate simultaneously.
Collapse
Affiliation(s)
- Stefano Gambera
- Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain
| | - Ander Abarrategi
- Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain
- Haematopoietic Stem Cell Lab, The Francis Crick Institute, London, NW1 1AT, UK
| | | | - Álvaro Morales-Molina
- Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain
| | - Josep Roma
- Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Hospital, Barcelona, 08035, Spain
| | - Arantzazu Alfranca
- Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain
- Immunology Department, Hospital Universitario de La Princesa, Madrid, 28006, Spain
| | - Javier García-Castro
- Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain.
| |
Collapse
|
15
|
Gambera S, Abarrategi A, Rodríguez-Milla MA, Mulero F, Menéndez ST, Rodriguez R, Navarro S, García-Castro J. Role of Activator Protein-1 Complex on the Phenotype of Human Osteosarcomas Generated from Mesenchymal Stem Cells. Stem Cells 2018; 36:1487-1500. [PMID: 30001480 DOI: 10.1002/stem.2869] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 05/09/2018] [Accepted: 05/28/2018] [Indexed: 12/13/2022]
Abstract
Osteosarcoma (OS) is a highly aggressive bone tumor that usually arises intramedullary at the extremities of long bones. Due to the fact that the peak of incidence is in the growth spurt of adolescence, the specific anatomical location, and the heterogeneity of cells, it is believed that osteosarcomagenesis is a process associated with bone development. Different studies in murine models showed that the tumor-initiating cell in OS could be an uncommitted mesenchymal stem cell (MSC) developing in a specific bone microenvironment. However, only a few studies have reported transgene-induced human MSCs transformation and mostly obtained undifferentiated sarcomas. In our study, we demonstrate that activator protein 1 family members induce osteosarcomagenesis in immortalized hMSC. c-JUN or c-JUN/c-FOS overexpression act as tumorigenic factors generating OS with fibroblastic or pleomorphic osteoblastic phenotypes, respectively. Stem Cells 2018;36:1487-1500.
Collapse
Affiliation(s)
- Stefano Gambera
- Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain
| | - Ander Abarrategi
- Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain.,Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | | | - Francisca Mulero
- Molecular Image Core Unit, Spanish National Cancer Research Centre, Madrid, Spain
| | - Sofía T Menéndez
- Hospital Universitario Central de Asturias-Instituto de Investigación Sanitaria del Principado de Asturias and, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,CIBER de Cáncer (CIBERONC), Madrid, Spain
| | - René Rodriguez
- Hospital Universitario Central de Asturias-Instituto de Investigación Sanitaria del Principado de Asturias and, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,CIBER de Cáncer (CIBERONC), Madrid, Spain
| | - Samuel Navarro
- CIBER de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, University of Valencia, Valencia, Spain
| | | |
Collapse
|
16
|
Abarrategi A, Mian SA, Passaro D, Rouault-Pierre K, Grey W, Bonnet D. Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches. J Exp Med 2018; 215:729-743. [PMID: 29453226 PMCID: PMC5839768 DOI: 10.1084/jem.20172139] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 01/19/2018] [Accepted: 01/30/2018] [Indexed: 12/11/2022] Open
Abstract
Xenotransplantation of patient-derived samples in mouse models has been instrumental in depicting the role of hematopoietic stem and progenitor cells in the establishment as well as progression of hematological malignancies. The foundations for this field of research have been based on the development of immunodeficient mouse models, which provide normal and malignant human hematopoietic cells with a supportive microenvironment. Immunosuppressed and genetically modified mice expressing human growth factors were key milestones in patient-derived xenograft (PDX) models, highlighting the importance of developing humanized microenvironments. The latest major improvement has been the use of human bone marrow (BM) niche-forming cells to generate human-mouse chimeric BM tissues in PDXs, which can shed light on the interactions between human stroma and hematopoietic cells. Here, we summarize the methods used for human hematopoietic cell xenotransplantation and their milestones and review the latest approaches in generating humanized BM tissues in mice to study human normal and malignant hematopoiesis.
Collapse
Affiliation(s)
- Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
| | - Syed A Mian
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
- Department of Haematological Medicine, King's College London School of Medicine, London, England, UK
| | - Diana Passaro
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
| | - Kevin Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, England, UK
| | - William Grey
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, England, UK
| |
Collapse
|
17
|
Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D. Preclinical modeling of myelodysplastic syndromes. Leukemia 2017; 31:2702-2708. [PMID: 28663577 PMCID: PMC5729336 DOI: 10.1038/leu.2017.172] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 04/25/2017] [Accepted: 05/23/2017] [Indexed: 12/12/2022]
Abstract
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.
Collapse
Affiliation(s)
- K Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - S A Mian
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - M Goulard
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
| | - A Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - A Di Tulio
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - A E Smith
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
- King’s College Hospital, Department of Haematology, London, UK
| | - A Mohamedali
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - S Best
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - A-M Nloga
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | | | - L Ades
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | - C Chomienne
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Cell Biology Department, Saint Louis Hospital, APHP, Paris, France
| | - P Fenaux
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | - C Dosquet
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Cell Biology Department, Saint Louis Hospital, APHP, Paris, France
| | - G J Mufti
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
- King’s College Hospital, Department of Haematology, London, UK
| | - D Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| |
Collapse
|
18
|
Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun 2017; 8:1679. [PMID: 29162833 PMCID: PMC5698422 DOI: 10.1038/s41467-017-01834-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 10/19/2017] [Indexed: 12/30/2022] Open
Abstract
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances AraC-mediated killing of AML cells both in vitro and in vivo, thus abrogating any potential chemoresistance mechanisms involving DNA repair. Importantly, this combination of drugs does not affect normal long-term hematopoietic stem/progenitors. Moreover, the addition of CHK1i to AraC does not generate de novo mutations and in patients' samples where AraC is mutagenic, addition of CHK1i appears to eliminate the generation of mutant clones. Finally, we observe that persistent residual leukemic cells are quiescent and can become responsive to the treatment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration. This drug combination (AraC+CHK1i+G-CSF) will open the doors for a more efficient treatment of AML in the clinic.
Collapse
MESH Headings
- Animals
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Cell Line, Tumor
- Checkpoint Kinase 1/antagonists & inhibitors
- Cytarabine/administration & dosage
- Drug Resistance, Neoplasm
- Female
- Granulocyte Colony-Stimulating Factor/administration & dosage
- HL-60 Cells
- Hematopoiesis/drug effects
- Humans
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/pathology
- Male
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Mutation/drug effects
- Piperidines/administration & dosage
- Protein Kinase Inhibitors/administration & dosage
- Pyridines/administration & dosage
- Pyrroles/administration & dosage
- U937 Cells
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Alessandro Di Tullio
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
| | - Kevin Rouault-Pierre
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Chaterhouse Square, EC1M 6BQ, London, UK
| | - Ander Abarrategi
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
| | - Syed Mian
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
- King's College London School of Medicine, Department of Haematological Medicine, The Rayne Institute, 123 Coldharbour Lane, SE5 9NU, London, UK
| | - William Grey
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
| | - John Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Chaterhouse Square, EC1M 6BQ, London, UK
| | - Aengus Stewart
- Bioinformatic Core, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK
| | | | - Dominique Bonnet
- Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT, London, UK.
| |
Collapse
|
19
|
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P, Bhaw L, Diana G, Lassailly F, Gribben J, Bonnet D. Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell 2017; 32:324-341.e6. [PMID: 28870739 PMCID: PMC5598545 DOI: 10.1016/j.ccell.2017.08.001] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 04/25/2017] [Accepted: 08/01/2017] [Indexed: 12/11/2022]
Abstract
The biological and clinical behaviors of hematological malignancies can be influenced by the active crosstalk with an altered bone marrow (BM) microenvironment. In the present study, we provide a detailed picture of the BM vasculature in acute myeloid leukemia using intravital two-photon microscopy. We found several abnormalities in the vascular architecture and function in patient-derived xenografts (PDX), such as vascular leakiness and increased hypoxia. Transcriptomic analysis in endothelial cells identified nitric oxide (NO) as major mediator of this phenotype in PDX and in patient-derived biopsies. Moreover, induction chemotherapy failing to restore normal vasculature was associated with a poor prognosis. Inhibition of NO production reduced vascular permeability, preserved normal hematopoietic stem cell function, and improved treatment response in PDX.
Collapse
Affiliation(s)
- Diana Passaro
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Alessandro Di Tullio
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Kevin Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Katie Foster
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Linda Ariza-McNaughton
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Beatriz Montaner
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Probir Chakravarty
- Bioinformatic Core Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Leena Bhaw
- Advanced Sequencing Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Giovanni Diana
- MRC Centre for Developmental Neurobiology, King's College London, London, UK
| | - François Lassailly
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - John Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
| |
Collapse
|
20
|
Passaro D, Abarrategi A, Foster K, Ariza-McNaughton L, Bonnet D. Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging. J Vis Exp 2017:55914. [PMID: 28809828 PMCID: PMC5613813 DOI: 10.3791/55914] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Human hematopoietic stem cells (HSCs) reside in the bone marrow (BM) niche, an intricate, multifactorial network of components producing cytokines, growth factors, and extracellular matrix. The ability of HSCs to remain quiescent, self-renew or differentiate, and acquire mutations and become malignant depends upon the complex interactions they establish with different stromal components. To observe the crosstalk between human HSCs and the human BM niche in physiological and pathological conditions, we designed a protocol to ectopically model and image a humanized BM niche in immunodeficient mice. We show that the use of different cellular components allows for the formation of humanized structures and the opportunity to sustain long-term human hematopoietic engraftment. Using two-photon microscopy, we can live-image these structures in situ at the single-cell resolution, providing a powerful new tool for the functional characterization of the human BM microenvironment and its role in regulating normal and malignant hematopoiesis.
Collapse
Affiliation(s)
- Diana Passaro
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute
| | - Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute
| | - Katie Foster
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute
| | | | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute;
| |
Collapse
|
21
|
Civantos A, Martínez-Campos E, Ramos V, Elvira C, Gallardo A, Abarrategi A. Titanium Coatings and Surface Modifications: Toward Clinically Useful Bioactive Implants. ACS Biomater Sci Eng 2017; 3:1245-1261. [DOI: 10.1021/acsbiomaterials.6b00604] [Citation(s) in RCA: 182] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Ana Civantos
- Tissue
Engineering Group, Institute of Biofunctional Studies, Associated
Unit to the Institute of Polymer Science and Technology (CSIC), Pharmacy
Faculty, Complutense University of Madrid (UCM), Paseo Juan XXIII 1, 28040 Madrid, Spain
- Polymer
Functionalization Group, Institute of Polymer Science and Technology, ICTP-CSIC, Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Enrique Martínez-Campos
- Tissue
Engineering Group, Institute of Biofunctional Studies, Associated
Unit to the Institute of Polymer Science and Technology (CSIC), Pharmacy
Faculty, Complutense University of Madrid (UCM), Paseo Juan XXIII 1, 28040 Madrid, Spain
- Polymer
Functionalization Group, Institute of Polymer Science and Technology, ICTP-CSIC, Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Viviana Ramos
- Tissue
Engineering Group, Institute of Biofunctional Studies, Associated
Unit to the Institute of Polymer Science and Technology (CSIC), Pharmacy
Faculty, Complutense University of Madrid (UCM), Paseo Juan XXIII 1, 28040 Madrid, Spain
- Noricum S.L., San Sebastián
de los Reyes, Av. Fuente Nueva, 14, 28703 Madrid, Spain
| | - Carlos Elvira
- Polymer
Functionalization Group, Institute of Polymer Science and Technology, ICTP-CSIC, Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Alberto Gallardo
- Polymer
Functionalization Group, Institute of Polymer Science and Technology, ICTP-CSIC, Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Ander Abarrategi
- Haematopoietic
Stem Cell Laboratory, The Francis Crick Institute, 1 Midland
Road, NW1 1AT London, U.K
| |
Collapse
|
22
|
Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribben J, Mufti G, Bonnet D. Versatile humanized niche model enables study of normal and malignant human hematopoiesis. J Clin Invest 2017; 127:543-548. [PMID: 28067666 PMCID: PMC5272182 DOI: 10.1172/jci89364] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 11/17/2016] [Indexed: 12/12/2022] Open
Abstract
The BM niche comprises a tightly controlled microenvironment formed by specific tissue and cells that regulates the behavior of hematopoietic stem cells (HSCs). Here, we have provided a 3D model that is tunable in different BM niche components and useful, both in vitro and in vivo, for studying the maintenance of normal and malignant hematopoiesis. Using scaffolds, we tested the capacity of different stromal cell types to support human HSCs. Scaffolds coated with human mesenchymal stromal cells (hMSCs) proved to be superior in terms of HSC engraftment and long-term maintenance when implanted in vivo. Moreover, we found that hMSC-coated scaffolds can be modulated to form humanized bone tissue, which was also able to support human HSC engraftment. Importantly, hMSC-coated humanized scaffolds were able to support the growth of leukemia patient cells in vivo, including the growth of samples that would not engraft the BM of immunodeficient mice. These results demonstrate that an s.c. implantation approach in a 3D carrier scaffold seeded with stromal cells is an effective in vivo niche model for studying human hematopoiesis. The various niche components of this model can be changed depending on the context to improve the engraftment of nonengrafting acute myeloid leukemia (AML) samples.
Collapse
Affiliation(s)
- Ander Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| | - Katie Foster
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| | - Ashley Hamilton
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| | - Syed A. Mian
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
- King’s College London School of Medicine, Department of Haematological Medicine, London, United Kingdom
| | - Diana Passaro
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| | - John Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Ghulam Mufti
- King’s College London School of Medicine, Department of Haematological Medicine, London, United Kingdom
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| |
Collapse
|
23
|
Barba-Recreo P, Del Castillo Pardo de Vera JL, Georgiev-Hristov T, Ruiz Bravo-Burguillos E, Abarrategi A, Burgueño M, García-Arranz M. Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model. J Craniomaxillofac Surg 2015; 43:1161-8. [PMID: 26027865 DOI: 10.1016/j.jcms.2015.04.026] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 04/02/2015] [Accepted: 04/30/2015] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVES The main challenge in treating bisphosphonate-related osteonecrosis of the jaw (BRONJ) is the absence of an effective established treatment. We aimed to compare different potentially preventive treatments for BRONJ after dental extractions in zoledronic acid (ZA)-treated animals. We studied the local application of different combinations of adipose-derived stem cells (ASCs) with or without previous stimulation with bone morphogenetic protein 2 (BMP-2) and platelet-rich plasma (PRP) in rats. MATERIAL AND METHODS Fifty-six male Wistar rats were treated with ZA for 9 weeks. Dental extractions were performed in the eighth week, and the animals were divided into 4 groups. In group 1 (n = 14), alveolar coverage with mucoperiosteal flap was performed. In group 2 (n = 14), PRP was applied over the sockets and covered with the flap. In group 3 (n = 15), allogeneic ASCs with PRP were applied and covered with the flap. In group 4 (n = 13), animals were treated with ASCs cultured with BMP-2, PRP, and flap coverage. Histologic, fluorescence, and radiologic studies of the maxillae were performed. RESULTS ASC-treated animals showed lower frequency of osteonecrosis (14% vs 50%, p = 0.007) and greater bone turnover (p = 0.024) and osteoclast count (p = 0.045) than those not receiving the ASC treatment. CONCLUSIONS In this high-risk model, ASC-based treatments seem to prevent BRONJ more effectively than mucosal flap with or without PRP. The combination of ASCs and PRP appears to be synergistic, and the addition of BMP-2 could further improve the results.
Collapse
Affiliation(s)
- Paula Barba-Recreo
- Department of Oral and Maxillofacial Surgery (Head: Miguel Burgueño), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
| | - Jose Luis Del Castillo Pardo de Vera
- Department of Oral and Maxillofacial Surgery (Head: Miguel Burgueño), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - Tihomir Georgiev-Hristov
- Cell Therapy Laboratory (Head: Damián García Olmo), Instituto de Investigación Sanitario Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain; Department of General Surgery, Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain
| | | | - Ander Abarrategi
- Cellular Biotechnology Unit, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km 2.200, 28220 Majadahonda, Spain; Haematopoietic Stem Cell Laboratory, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, United Kingdom
| | - Miguel Burgueño
- Department of Oral and Maxillofacial Surgery (Head: Miguel Burgueño), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain; Department of Surgery, Faculty of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo s/n, 28029 Madrid, Spain
| | - Mariano García-Arranz
- Cell Therapy Laboratory (Head: Damián García Olmo), Instituto de Investigación Sanitario Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain; Department of Surgery, Faculty of Medicine, Universidad Autónoma de Madrid, C/ Arzobispo Morcillo s/n, 28029 Madrid, Spain
| |
Collapse
|
24
|
Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J, Rodriguez R. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 2015; 72:3097-113. [DOI: 10.1007/s00018-015-1918-y] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Revised: 04/24/2015] [Accepted: 04/27/2015] [Indexed: 02/06/2023]
|
25
|
Rubio R, Abarrategi A, Garcia-Castro J, Martinez-Cruzado L, Suarez C, Tornin J, Santos L, Astudillo A, Colmenero I, Mulero F, Rosu-Myles M, Menendez P, Rodriguez R. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells. Stem Cells 2014; 32:1136-48. [PMID: 24446210 DOI: 10.1002/stem.1647] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 12/21/2013] [Indexed: 12/27/2022]
Abstract
The cellular microenvironment plays a relevant role in cancer development. We have reported that mesenchymal stromal/stem cells (MSCs) deficient for p53 alone or together with RB (p53(-/-)RB(-/-)) originate leiomyosarcoma after subcutaneous (s.c.) inoculation. Here, we show that intrabone or periosteal inoculation of p53(-/-) or p53(-/-)RB(-/-) bone marrow- or adipose tissue-derived MSCs originated metastatic osteoblastic osteosarcoma (OS). To assess the contribution of bone environment factors to OS development, we analyzed the effect of the osteoinductive factor bone morphogenetic protein-2 (BMP-2) and calcified substrates on p53(-/-)RB(-/-) MSCs. We show that BMP-2 upregulates the expression of osteogenic markers in a WNT signaling-dependent manner. In addition, the s.c. coinfusion of p53(-/-)RB(-/-) MSCs together with BMP-2 resulted in appearance of tumoral osteoid areas. Likewise, when p53(-/-)RB(-/-) MSCs were inoculated embedded in a calcified ceramic scaffold composed of hydroxyapatite and tricalciumphosphate (HA/TCP), tumoral bone formation was observed in the surroundings of the HA/TCP scaffold. Moreover, the addition of BMP-2 to the ceramic/MSC implants further increased the tumoral osteoid matrix. Together, these data indicate that bone microenvironment signals are essential to drive OS development.
Collapse
Affiliation(s)
- Ruth Rubio
- GENyO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Government, Granada, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Abarrategi A, Perez-Tavarez R, Rodriguez-Milla MA, Cubillo I, Mulero F, Alfranca A, Lopez-Lacomba JL, García-Castro J. In vivo ectopic implantation model to assess human mesenchymal progenitor cell potential. Stem Cell Rev Rep 2014; 9:833-46. [PMID: 23934266 PMCID: PMC3834175 DOI: 10.1007/s12015-013-9464-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Clinical interest on human mesenchymal progenitor cells (hMPC) relies on their potential applicability in cell-based therapies. An in vitro characterization is usually performed in order to define MPC potency. However, in vitro predictions not always correlate with in vivo results and thus there is no consensus in how to really assess cell potency. Our goal was to provide an in vivo testing method to define cell behavior before therapeutic usage, especially for bone tissue engineering applications. In this context, we wondered whether bone marrow stromal cells (hBMSC) would proceed in an osteogenic microenvironment. Based on previous approaches, we developed a fibrin/ceramic/BMP-2/hBMSCs compound. We implanted the compound during only 2 weeks in NOD-SCID mice, either orthotopically to assess its osteoinductive property or subcutaneously to analyze its adequacy as a cell potency testing method. Using fluorescent cell labeling and immunohistochemistry techniques, we could ascertain cell differentiation to bone, bone marrow, cartilage, adipocyte and fibrous tissue. We observed differences in cell potential among different batches of hBMSCs, which did not strictly correlate with in vitro analyses. Our data indicate that the method we have developed is reliable, rapid and reproducible to define cell potency, and may be useful for testing cells destined to bone tissue engineering purposes. Additionally, results obtained with hMPCs from other sources indicate that our method is suitable for testing any potentially implantable mesenchymal cell. Finally, we propose that this model could successfully be employed for bone marrow niche and bone tumor studies.
Collapse
Affiliation(s)
- Ander Abarrategi
- Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Med 2014; 3:1099-111. [PMID: 24961511 PMCID: PMC4302662 DOI: 10.1002/cam4.291] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 05/29/2014] [Accepted: 05/30/2014] [Indexed: 12/20/2022] Open
Abstract
Lung cancer is the top cause of cancer-related deceases. One of the reasons is the development of resistance to the chemotherapy treatment. In particular, cancer stem cells (CSCs), can escape treatment and regenerate the bulk of the tumor. In this article, we describe a comparison between cancer cells resistant to cisplatin and CSCs, both derived from the non-small-cell lung cancer cell lines H460 and A549. Cisplatin-resistant cells were obtained after a single treatment with the drug. CSCs were isolated by culture in defined media, under nonadherent conditions. The isolated CSCs were clonogenic, could be differentiated into adherent cells and were less sensitive to cisplatin than the original cells. Cisplatin resistant and CSCs were able to generate primary tumors and to metastasize when injected into immunodeficient Nu/Nu mice, although they formed smaller tumors with a larger latency than untreated cells. Notably, under appropriated proportions, CSCs synergized with differentiated cells to form larger tumors. CSCs also showed increased capacity to induce angiogenesis in Nu/Nu mice. Conversely, H460 cisplatin-resistant cells showed increased tendency to develop bone metastasis. Gene expression analysis showed that several genes involved in tumor development and metastasis (EGR1, COX2, MALAT1, AKAP12, ADM) were similarly induced in CSC and cisplatin-resistant H460 cells, in agreement with a close similarity between these two cell populations. Cells with the characteristic growth properties of CSCs were also isolated from surgical samples of 18 out of 44 lung cancer patients. A significant correlation (P = 0.028) was found between the absence of CSCs and cisplatin sensitivity.
Collapse
Affiliation(s)
- Blanca D Lopez-Ayllon
- Instituto de Investigaciones Biomédicas CSIC/UAM, Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Spain
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Guzmán R, Nardecchia S, Gutiérrez MC, Ferrer ML, Ramos V, del Monte F, Abarrategi A, López-Lacomba JL. Chitosan scaffolds containing calcium phosphate salts and rhBMP-2: in vitro and in vivo testing for bone tissue regeneration. PLoS One 2014; 9:e87149. [PMID: 24504411 PMCID: PMC3913585 DOI: 10.1371/journal.pone.0087149] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Accepted: 12/18/2013] [Indexed: 11/23/2022] Open
Abstract
Numerous strategies that are currently used to regenerate bone depend on employing biocompatible materials exhibiting a scaffold structure. These scaffolds can be manufactured containing particular active compounds, such as hydroxyapatite precursors and/or different growth factors to enhance bone regeneration process. Herein, we have immobilized calcium phosphate salts (CPS) and bone morphogenetic protein 2 (BMP-2) – combined or alone – into chitosan scaffolds using ISISA process. We have analyzed whether the immobilized bone morphogenetic protein preserved its osteoinductive capability after manufacturing process as well as BMP-2 in vitro release kinetic. We have also studied both the in vitro and in vivo biocompatibility of the resulting scaffolds using a rabbit model. Results indicated that rhBMP-2 remained active in the scaffolds after the manufacturing process and that its release kinetic was different depending on the presence of CPS. In vitro and in vivo findings showed that cells grew more in scaffolds with both CPS and rhBMP-2 and that these scaffolds induced more bone formation in rabbit tibia. Thus chitosan scaffolds containing both CPS and rhBMP-2 were more osteoinductive than their counterparts alone indicating that could be useful for bone regeneration purposes, such as some applications in dentistry.
Collapse
Affiliation(s)
- Rodrigo Guzmán
- Instituto de Estudios Biofuncionales, Universidad Complutense de Madrid, Madrid, Spain
| | - Stefania Nardecchia
- Instituto de Ciencia de Materiales de Madrid-ICMM, Consejo Superior de Investigaciones Científicas-CSIC, Campus de Cantoblanco, Madrid, Spain
| | - María C. Gutiérrez
- Instituto de Ciencia de Materiales de Madrid-ICMM, Consejo Superior de Investigaciones Científicas-CSIC, Campus de Cantoblanco, Madrid, Spain
| | - María Luisa Ferrer
- Instituto de Ciencia de Materiales de Madrid-ICMM, Consejo Superior de Investigaciones Científicas-CSIC, Campus de Cantoblanco, Madrid, Spain
| | - Viviana Ramos
- Noricum Inc, Departamento de I+D, Parque Científico de Madrid, Tres Cantos, Madrid, Spain
| | - Francisco del Monte
- Instituto de Ciencia de Materiales de Madrid-ICMM, Consejo Superior de Investigaciones Científicas-CSIC, Campus de Cantoblanco, Madrid, Spain
- * E-mail: (JLL-L); (AA); (FdM)
| | - Ander Abarrategi
- Instituto de Estudios Biofuncionales, Universidad Complutense de Madrid, Madrid, Spain
- * E-mail: (JLL-L); (AA); (FdM)
| | - José Luis López-Lacomba
- Instituto de Estudios Biofuncionales, Universidad Complutense de Madrid, Madrid, Spain
- * E-mail: (JLL-L); (AA); (FdM)
| |
Collapse
|
29
|
Abarrategi A, Moreno-Vicente C, Martínez-Vázquez FJ, Civantos A, Ramos V, Sanz-Casado JV, Martínez-Corriá R, Perera FH, Mulero F, Miranda P, López-Lacomba JL. Biological properties of solid free form designed ceramic scaffolds with BMP-2: in vitro and in vivo evaluation. PLoS One 2012; 7:e34117. [PMID: 22470527 PMCID: PMC3314706 DOI: 10.1371/journal.pone.0034117] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 02/22/2012] [Indexed: 11/18/2022] Open
Abstract
Porous ceramic scaffolds are widely studied in the tissue engineering field due to their potential in medical applications as bone substitutes or as bone-filling materials. Solid free form (SFF) fabrication methods allow fabrication of ceramic scaffolds with fully controlled pore architecture, which opens new perspectives in bone tissue regeneration materials. However, little experimentation has been performed about real biological properties and possible applications of SFF designed 3D ceramic scaffolds. Thus, here the biological properties of a specific SFF scaffold are evaluated first, both in vitro and in vivo, and later scaffolds are also implanted in pig maxillary defect, which is a model for a possible application in maxillofacial surgery. In vitro results show good biocompatibility of the scaffolds, promoting cell ingrowth. In vivo results indicate that material on its own conducts surrounding tissue and allow cell ingrowth, thanks to the designed pore size. Additional osteoinductive properties were obtained with BMP-2, which was loaded on scaffolds, and optimal bone formation was observed in pig implantation model. Collectively, data show that SFF scaffolds have real application possibilities for bone tissue engineering purposes, with the main advantage of being fully customizable 3D structures.
Collapse
Affiliation(s)
- Ander Abarrategi
- Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain
- Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | | | | | - Ana Civantos
- Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain
| | - Viviana Ramos
- Departamento de I+D, Noricum S.L., San Sebastián de los Reyes, Madrid, Spain
| | | | | | - Fidel Hugo Perera
- Departamento de Ingeniería Mecánica, Energética y de los Materiales, Universidad de Extremadura, Badajoz, Extremadura, Spain
| | - Francisca Mulero
- Molecular Imaging Core Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
| | - Pedro Miranda
- Departamento de Ingeniería Mecánica, Energética y de los Materiales, Universidad de Extremadura, Badajoz, Extremadura, Spain
- * E-mail: (JLL); (PM)
| | - José Luís López-Lacomba
- Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain
- * E-mail: (JLL); (PM)
| |
Collapse
|
30
|
Abarrategi A, Fernandez-Valle ME, Desmet T, Castejón D, Civantos A, Moreno-Vicente C, Ramos V, Sanz-Casado JV, Martínez-Vázquez FJ, Dubruel P, Miranda P, López-Lacomba JL. Label-free magnetic resonance imaging to locate live cells in three-dimensional porous scaffolds. J R Soc Interface 2012; 9:2321-31. [PMID: 22442095 DOI: 10.1098/rsif.2012.0068] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Porous scaffolds are widely tested materials used for various purposes in tissue engineering. A critical feature of a porous scaffold is its ability to allow cell migration and growth on its inner surface. Up to now, there has not been a method to locate live cells deep inside a material, or in an entire structure, using real-time imaging and a non-destructive technique. Herein, we seek to demonstrate the feasibility of the magnetic resonance imaging (MRI) technique as a method to detect and locate in vitro non-labelled live cells in an entire porous material. Our results show that the use of optimized MRI parameters (4.7 T; repetition time = 3000 ms; echo time = 20 ms; resolution 39 × 39 µm) makes it possible to obtain images of the scaffold structure and to locate live non-labelled cells in the entire material, with a signal intensity higher than that obtained in the culture medium. In the current study, cells are visualized and located in different kinds of porous scaffolds. Moreover, further development of this MRI method might be useful in several three-dimensional biomaterial tests such as cell distribution studies, routine qualitative testing methods and in situ monitoring of cells inside scaffolds.
Collapse
Affiliation(s)
- A Abarrategi
- Institute of Biofunctional Studies, Nuclear Magnetic Resonance, Complutense University, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Over the last decade, genetic and cell biology studies have indicated that tumour growth is not only determined by malignant cancer cells themselves, but also by the tumour microenvironment. Cells present in the tumour microenvironment include fibroblasts, vascular, smooth muscle, adipocytes, immune cells and mesenchymal stem cells (MSC). The nature of the relationship between MSC and tumour cells appears dual and whether MSC are pro- or anti-tumorigenic is a subject of controversial reports. This review is focused on the role of MSC and bone marrow (BM) niches in cancer.
Collapse
Affiliation(s)
- Ander Abarrategi
- Unidad de Biotecnología Celular, Área Biología Celular y del Desarrollo, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | | | | | | | | |
Collapse
|
32
|
Lópiz-Morales Y, Abarrategi A, Ramos V, Moreno-Vicente C, López-Durán L, López-Lacomba JL, Marco F. In vivo comparison of the effects of rhBMP-2 and rhBMP-4 in osteochondral tissue regeneration. Eur Cell Mater 2010; 20:367-78. [PMID: 21154243 DOI: 10.22203/ecm.v020a30] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The aim of this work is to investigate the use of bone morphogenetic proteins (rhBMP-2, rhBMP-4) alone or in combination with cells delivered in a calcium alginate gel for the treatment of osteochondral defects. For this purpose, alginate gels were prepared mixing a 2% sodium alginate solution and a 200 mM calcium chloride solution (1:1). Osteochondral defects were created (4 mm wide, 5 mm deep) in the internal femoral condyle of rabbit knee and gels were directly formed into the defects. 3 months after surgery samples were harvested, gross morphology was documented and histological appearance was evaluated. The performed histological observations revealed subchondral bone regeneration in rhBMP-2 samples and moderate hyaline cartilage regeneration in rhBMP-4 samples. Thus, results indicate that alginate gel may serve as an appropriate delivery vehicle for rhBMP-2, rhBMP-4 and stromal cells. With this carrier material, differential behaviour between the evaluated proteins was observed. rhBMP-2 shows better restoration of subchondral bone in contrast to the superior efficiency of rhBMP-4 for hyaline cartilage repair.
Collapse
|
33
|
Abarrategi A, Lópiz-Morales Y, Ramos V, Civantos A, López-Durán L, Marco F, López-Lacomba JL. Chitosan scaffolds for osteochondral tissue regeneration. J Biomed Mater Res A 2010; 95:1132-41. [DOI: 10.1002/jbm.a.32912] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Revised: 05/11/2010] [Accepted: 06/07/2010] [Indexed: 11/11/2022]
|
34
|
Abarrategi A, García-Cantalejo J, Moreno-Vicente C, Civantos A, Ramos V, Casado JVS, Pérez-Rial S, Martńez-Corriá R, López-Lacomba JL. Gene expression profile on chitosan/rhBMP-2 films: A novel osteoinductive coating for implantable materials. Acta Biomater 2009; 5:2633-46. [PMID: 19342322 DOI: 10.1016/j.actbio.2009.02.031] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2008] [Revised: 02/06/2009] [Accepted: 02/10/2009] [Indexed: 01/27/2023]
Abstract
This study focusses on the gene expression profile related to a new rhBMP-2 carrier material, chitosan film. This film could be suitable for use as an osteoinductive coating of commercially available titanium implants. The developed material was characterized, biocompatibility was tested and the cellular response was extensively characterized by transcriptional expression studies. Finally, in vivo studies were carried out to confirm the osteoinductivity of the developed coating. Results show good material properties for cell adhesion and proliferation. Presented data show cellular differentiation to the osteoblastic phenotype due to rhBMP-2, with a 90% common transcriptional response between the control rhBMP-2 treatment and the developed chitosan/rhBMP-2 film. The growing surface also had an influence on the observed cellular response and was quantified as 7% of the total. These results indicate that both the growth factor and the material induce a cell response, but this is mainly driven by the osteoinductor factor. In vivo, new bone formation and early vascularization was observed around chitosan/rhBMP-2 coated titanium pieces implanted in mouse muscle. In contrast, control implants did not induce this reaction. This work, therefore, shows both in vitro and in vivo that chitosan/rhBMP-2 film is a promising osteoinductive coating for titanium implantable materials.
Collapse
Affiliation(s)
- Ander Abarrategi
- Instituto de Estudios Biofuncionales, Universidad Complutense, Paseo Juan XXIII 1, 28040 Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abarrategi A, Moreno-Vicente C, Ramos V, Aranaz I, Sanz Casado JV, López-Lacomba JL. Improvement of porous beta-TCP scaffolds with rhBMP-2 chitosan carrier film for bone tissue application. Tissue Eng Part A 2008; 14:1305-19. [PMID: 18491953 DOI: 10.1089/ten.tea.2007.0229] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Ceramic materials are osteoconductive matrices extensively used in bone tissue engineering approaches. The performance of these types of biomaterials can be greatly enhanced by the incorporation of bioactive agents and materials. It is previously reported that chitosan is a biocompatible, biodegradable material that enhances bone formation. In the other hand, bone morphogenetic protein-2 (BMP-2) is a well-known osteoinductive factor. In this work we coated porous beta-tricalcium phosphate (beta-TCP) scaffolds with recombinant human BMP-2 (rhBMP-2) carrier chitosan films and studied how they could modify the ceramic physicochemical properties, cellular response, and in vivo bone generation. Initial beta-TCP disks with an average diameter of 5.78 mm, 2.9 mm thickness, and 53% porosity were coated with a chitosan film. These coating properties were studied by X-ray diffraction, Fourier transform-infrared analysis, transmission electron microscopy, scanning electron microscopy, and energy dispersive X-ray analysis (EDX). Treatment modified the scaffold porous distribution and increased the average hardness. The biocompatibility did not seem to be altered. In addition, adhered C2C12 cells expressed alkaline phosphatase activity, related to cell differentiation toward osteogenic lineage, due to the incorporation of rhBMP-2. On the other hand, in vivo observations showed new bone formation 3 weeks after surgery, a much shorter time than control beta-TCP ceramics. These results suggest that developed coating improved porous beta-TCP scaffold for bone tissue applications and added osteoinductive properties.
Collapse
Affiliation(s)
- Ander Abarrategi
- Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Hortigüela MJ, Gutiérrez MC, Aranaz I, Jobbágy M, Abarrategi A, Moreno-Vicente C, Civantos A, Ramos V, López-Lacomba JL, Ferrer ML, del Monte F. Urea assisted hydroxyapatite mineralization on MWCNT/CHI scaffolds. ACTA ACUST UNITED AC 2008. [DOI: 10.1039/b815401e] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
37
|
Abarrategi A, Gutiérrez MC, Moreno-Vicente C, Hortigüela MJ, Ramos V, López-Lacomba JL, Ferrer ML, del Monte F. Multiwall carbon nanotube scaffolds for tissue engineering purposes. Biomaterials 2008; 29:94-102. [DOI: 10.1016/j.biomaterials.2007.09.021] [Citation(s) in RCA: 273] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Accepted: 09/18/2007] [Indexed: 10/22/2022]
|
38
|
Abarrategi A, Civantos A, Ramos V, Sanz Casado JV, López-Lacomba JL. Chitosan film as rhBMP2 carrier: delivery properties for bone tissue application. Biomacromolecules 2007; 9:711-8. [PMID: 18163540 DOI: 10.1021/bm701049g] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Tissue engineering approaches need biomaterials with suitable properties to provide an appropriate environment for cell attachment and growth. The performance of these biomaterials can be greatly enhanced through the incorporation of bioactive agents. For this reason, we developed chitosan films with cell-attachment ability, rhBMP-2 carrier capacity, and good in vivo performance, and we employ them as covering for implantable materials. In this work, we have tried to explain how the rh-BMP2 is delivered to the surroundings from the development chitosan films. Protein diffusion from film, film stability versus in vitro dissolution, and biodegradation were evaluated to study rhBMP-2 delivery. Our results show that chitosan film has sufficiently good features to be used as an rhBMP-2 carrier. A low diffusion rate was observed, which was sufficient to quickly induce an in vitro differentiation stimulus, although heavily activated films retain more than 80-85% of the protein on the film. On the other hand, we estimated that chitosan film dissolution due to initial acidification in the wound environment is no more than 15-20%. We also estimated chitosan film response to lysozyme and concluded that degradation via this process proceeded at a slow kinetic rate. In addition, rhBMP-2 in vitro activity after film processing, as well as in vivo film behavior, were studied. We confirm that rhBMP-2 remains active on the film and after release, both in vitro and in vivo. These results support the conclusion that the developed chitosan film allows sustained release of the rhBMP-2 osteoinductive protein and could be used as an activated coat for implant and surgical prosthesis.
Collapse
Affiliation(s)
- Ander Abarrategi
- Instituto de Estudios Biofuncionales, Universidad Complutense, Paseo Juan XXIII 1, 28040 Madrid, España
| | | | | | | | | |
Collapse
|
39
|
Ramos V, Rodríguez N, Henning I, Díaz M, Monachesi M, Rodríguez M, Abarrategi A, Correas-Magaña V, López-Lacomba J, Agulló E. Poly(ethylene glycol)-crosslinked N-methylene phosphonic chitosan. Preparation and characterization. Carbohydr Polym 2006. [DOI: 10.1016/j.carbpol.2005.12.025] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
López-Lacomba JL, García-Cantalejo JM, Sanz Casado JV, Abarrategi A, Correas Magaña V, Ramos V. Use of rhBMP-2 Activated Chitosan Films To Improve Osseointegration. Biomacromolecules 2006; 7:792-8. [PMID: 16529416 DOI: 10.1021/bm050859e] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Considering the design and development of biomaterials used in tissue engineering, not only is it important that they are biocompatible but also that they induce the desired cellular response for tissue regeneration. Chitosan, a biocompatible and bioresorbable polymer of N-acetylglucosamine and glucosamine is used in our work combined with recombinant human BMP-2 (rhBMP-2), a potentially useful activation factor for bone repair. In this way, we try to combine the biological and filmogenic properties of this biopolymer with the osseoinductive ability of the rhBMP-2. Results showed that the chitosan films employed, without and with rhBMP-2 activation, are able to support cellular growth and proliferation on them and that only the rhBMP-2 activated ones are able to differentiate from a myoblastic mouse cell line (C2C12) toward osteoblastic phenotype. Osseoinduction properties of rhBMP-2 activated films persist for a long storage time. The in vivo experiments performed confirm the expectative created by the in vitro results obtained and are an indication that rhBMP-2 activated chitosan films could be a very attractive biomaterial for the enhancement of osseointegration of surgical prostheses and implants and for the purpose of tissue engineering bone regeneration.
Collapse
Affiliation(s)
- J L López-Lacomba
- Instituto de Estudios Biofuncionales, Departamento de Química Física, Facultad de Farmacia, Universidad Complutense, Paseo Juan XXIII 1, 28040, Madrid, España, Spain.
| | | | | | | | | | | |
Collapse
|